1369626-40-3

Upstream product

• 1369627-65-5 7'-bromo-3'-(spiro[1,3]dioxolane)-1',2',3',4',4a',9a'-hexahydrospiro[imidazolidine-4,9'-xanthene]-2,5-dione 
• 1369627-74-6 9'-amino-7'-bromo-1',2',4',4a',9',9a'-hexahydrospiro[[1,3]dioxolane-2,3'-xanthene]-9'-carboxylic acid 
• 1369627-75-7 methyl 9'-amino-7'-bromo-1',2',4',4a',9',9a'-hexahydrospiro[[1,3]dioxolane-2,3'-xanthene]-9'-carboxylate hydrochloride 
• 1369627-76-8 7'-bromo-1-methyl-3'-(spiro[1,3]dioxolane)-2-thioxo-1',2',3',4',4a',9a'-hexahydrospiro[imidazolidine-4,9'-xanthene]-5-one 
• 1369627-77-9 2-amino-7'-bromo-3'-(spiro[1,3]dioxolane)-1-methyl-1',2',3',4',4a',9a'-hexahydrospiro[imidazole-4,9'-xanthene]-5(1H)-one 
• 1369627-78-0 2-amino-7'-bromo-1-methyl-1',4',4a',9a'-tetrahydrospiro[imidazole-4,9'-xanthene]-3',5(1H,2'H)-dione 
• 328956-61-2 3-fluoro-5-chlorophenylboronic acid 
• 52817-12-6 6-bromo-4-oxo-4H-chromene-3-carbaldehyde 

Relevant academic research and scientific papers

COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES

The invention provides novel tricyclic compounds of Formula I' that inhibit β-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.